| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JHEP.2017.06.026 |
| P698 | PubMed publication ID | 28687477 |
| P50 | author | Josep M. Llovet | Q37393125 |
| Jordi Bruix | Q37393143 | ||
| Ann-Lii Cheng | Q38639483 | ||
| Keiko Nakajima | Q90326333 | ||
| Gerold Meinhardt | Q114779892 | ||
| Yoriko De Sanctis | Q114779894 | ||
| P2507 | corrigendum / erratum | Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] | Q58020766 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P577 | publication date | 2017-07-04 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies |
| Q89558091 | 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations |
| Q90703374 | A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy |
| Q96431730 | ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma |
| Q100427917 | AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway |
| Q92081816 | ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib |
| Q58800845 | ATPase inhibitory factor 1 inhibition improves the antitumor of YC-1 against hepatocellular carcinoma |
| Q92414362 | Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study |
| Q92989160 | Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study |
| Q90644116 | Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib |
| Q64895129 | C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. |
| Q50132420 | Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. |
| Q92620201 | Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China |
| Q91709074 | Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma |
| Q93063612 | Current options and future possibilities for the systemic treatment of hepatocellular carcinoma |
| Q97543823 | Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy |
| Q93159937 | Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma |
| Q64947984 | Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. |
| Q94603190 | Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma |
| Q89966736 | Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma |
| Q90631498 | Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis |
| Q49884605 | Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials |
| Q53837211 | Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. |
| Q90643433 | Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
| Q92360281 | Emerging trends in modeling human liver disease in vitro |
| Q58118311 | Epidemiology and Management of Hepatocellular Carcinoma |
| Q91942671 | Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib |
| Q97543814 | Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study |
| Q59335494 | Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months |
| Q58115803 | Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53 |
| Q91557675 | From NASH to HCC: current concepts and future challenges |
| Q64089290 | Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib |
| Q47576283 | Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. |
| Q58020832 | Hepatocellular carcinoma |
| Q98195434 | Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence |
| Q92104133 | Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets |
| Q64084335 | Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) |
| Q64102454 | Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials |
| Q100725420 | Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study |
| Q92658310 | Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study |
| Q90451560 | Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib |
| Q91651633 | Increased Expression of Myeloid-Derived Suppressor Cells in Patients with HBV-Related Hepatocellular Carcinoma |
| Q92353495 | Insights into the success and failure of systemic therapy for hepatocellular carcinoma |
| Q64087592 | Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone |
| Q41670848 | Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells |
| Q55712348 | Macroscopic Portal Vein Thrombosis in HCC Patients. |
| Q58020775 | Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial |
| Q57143856 | Molecular therapies and precision medicine for hepatocellular carcinoma |
| Q90052869 | New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma |
| Q93384282 | No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma |
| Q90403214 | Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model |
| Q55395077 | Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. |
| Q92989291 | Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma |
| Q92625988 | Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma |
| Q53818658 | Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. |
| Q89737464 | Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis |
| Q64940188 | Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal |
| Q53708416 | Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy. |
| Q91147762 | Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma |
| Q94543854 | Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors |
| Q90076663 | Significantly different expression levels of microRNAs associated with vascular invasion in hepatocellular carcinoma and their prognostic significance after surgical resection |
| Q90041926 | Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital |
| Q92217096 | Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1 |
| Q91879742 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial |
| Q92980217 | Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma |
| Q52649739 | Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells. |
| Q97542924 | Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies |
| Q57301434 | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
| Q57067866 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? |
| Q94526793 | The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy |
| Q57053754 | The Role of Angiogenesis in Hepatocellular Carcinoma |
| Q94606142 | The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib |
| Q64258657 | The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma |
| Q56384328 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study |
| Q98288243 | Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma |
| Q57491231 | Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy |
| Q64116906 | Update on hepatocellular carcinoma: Pathologists' review |
| Q92642750 | Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment |
| Q90147191 | Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma |
| Q90285921 | Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma |
| Q58020766 | Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008] | main subject | P921 |
Search more.